Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 3/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21688056 | 0.97 | CYP11B1 (0.32) | PTGER4CYP11B1CYP11B2GABRA1GABRG2 | |
| SCHEMBL21688105 | 0.94 | PTGER4 (0.33) | PTGER4RORCCYP11B1CYP11B2 | |
| SCHEMBL21688237 | 0.93 | PTGER4 (0.33) | PTGER4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL21688174 | 0.92 | PTGER4 (0.33) | PTGER4RORCCYP11B1CYP11B2 | |
| SCHEMBL21687663 | 0.91 | PTGER4 (0.33) | PTGER4RORC | |
| SCHEMBL21687481 | 0.91 | NR3C1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL21687685 | 0.90 | PTGER4 (0.34) | PTGER4RORC | |
| SCHEMBL21688244 | 0.89 | GABRA1 (0.34) | PTGER4CYP11B1CYP11B2GABRA1GABRG2 | |
| SCHEMBL21688185 | 0.89 | CYP11B1 (0.32) | PTGER4CYP11B1CYP11B2 | |
| SCHEMBL21687674 | 0.88 | PTGER4 (0.33) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-12-14 | — | — | US | disclosed |
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | CRY1, CCNL2, CCNE2 | PTGER4 553/4885RORC 1486/4885CYP11B1 1222/4885 |
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | CRY1, CCNL2, CCNE2 | PTGER4 553/4885RORC 1486/4885CYP11B1 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.